Malignancy in Renal Transplant Recipients / 대한이식학회지
The Journal of the Korean Society for Transplantation
;
: 130-134, 2009.
Article
in Korean
| WPRIM
| ID: wpr-76630
ABSTRACT
With improved management of infectious and cardiovascular complications of renal transplant recipients, prolonged survival with long-term follow up duration, and increasing age of patients, cancer became an increasingly important cause of morbidity and mortality in transplant patients. Literatures indicate three to fivefold incidence of malignancy in solid organ transplant recipients compared with that of general population. Certain types of malignancy, such as skin cancer, Kaposi's sarcoma, lymphoma, cervical, oral and anogenital cancer, hepatocelluar and renal cell carcinoma are particularly reported to be high in incidence. Reduction of immunosuppressive medication is the first step to be considered for the management, especially for virus-associated cancer. The inhibitor of mammalian target of rapamycin(mTORi) suppresses the growth and proliferation of tumors in various animal models, cured Kaposi's sarcoma and seems to reduce the incidence of de novo malignancies of renal transplant recipients, and is therefore a valuable option for the management of cancer of these patients without increment of the risk of graft rejection.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sarcoma, Kaposi
/
Skin Neoplasms
/
Carcinoma, Renal Cell
/
Incidence
/
Follow-Up Studies
/
Kidney Transplantation
/
Resin Cements
/
Transplants
/
Models, Animal
/
Early Detection of Cancer
Type of study:
Diagnostic study
/
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
/
Screening study
Limits:
Humans
Language:
Korean
Journal:
The Journal of the Korean Society for Transplantation
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS